Bayer HealthCare to present new Xarelto data at ACC 2012

Bayer HealthCare will be presenting new clinical trial data on its promising therapy Xarelto at the forthcoming American College of Cardiology (ACC) annual scientific sessions.

The company will attend ACC 2012 in Chicago to showcase results from the phase III Einstein-PE study, which assessed the performance of Xarelto for acute symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis (DVT).

Bayer's rivaroxaban-based therapy used an oral single-drug approach, with the aim of demonstrating benefits compared to initial subcutaneous enoxaparin followed by a vitamin K antagonist, the current standard of care.

Einstein-PE is one of three studies conducted under the global phase III Einstein programme, which involved almost 10,000 patients altogether.

Xarelto has been developed jointly by Bayer HealthCare and Janssen Pharmaceuticals, and is thought to offer billion-dollar blockbuster sales potential.

Last week, the UK's National Institute for Health and Clinical Excellence asked Bayer to provide more clinical data to support a potential UK recommendation of the drug as a treatment for DVT.